González-Beltrán Alejandra N, Yong May Y, Dancey Gairin, Begent Richard
Computational and Systems Medicine, University College London, Cruciform Building, Gower Street, London, UK.
BMC Res Notes. 2012 Jan 6;5:10. doi: 10.1186/1756-0500-5-10.
Biology, biomedicine and healthcare have become data-driven enterprises, where scientists and clinicians need to generate, access, validate, interpret and integrate different kinds of experimental and patient-related data. Thus, recording and reporting of data in a systematic and unambiguous fashion is crucial to allow aggregation and re-use of data. This paper reviews the benefits of existing biomedical data standards and focuses on key elements to record experiments for therapy development. Specifically, we describe the experiments performed in molecular, cellular, animal and clinical models. We also provide an example set of elements for a therapy tested in a phase I clinical trial.
We introduce the Guidelines for Information About Therapy Experiments (GIATE), a minimum information checklist creating a consistent framework to transparently report the purpose, methods and results of the therapeutic experiments. A discussion on the scope, design and structure of the guidelines is presented, together with a description of the intended audience. We also present complementary resources such as a classification scheme, and two alternative ways of creating GIATE information: an electronic lab notebook and a simple spreadsheet-based format. Finally, we use GIATE to record the details of the phase I clinical trial of CHT-25 for patients with refractory lymphomas. The benefits of using GIATE for this experiment are discussed.
While data standards are being developed to facilitate data sharing and integration in various aspects of experimental medicine, such as genomics and clinical data, no previous work focused on therapy development. We propose a checklist for therapy experiments and demonstrate its use in the 131Iodine labeled CHT-25 chimeric antibody cancer therapy. As future work, we will expand the set of GIATE tools to continue to encourage its use by cancer researchers, and we will engineer an ontology to annotate GIATE elements and facilitate unambiguous interpretation and data integration.
生物学、生物医学和医疗保健已成为数据驱动型事业,科学家和临床医生需要生成、获取、验证、解释和整合不同类型的实验数据及与患者相关的数据。因此,以系统且明确的方式记录和报告数据对于数据的汇总和再利用至关重要。本文回顾了现有生物医学数据标准的益处,并着重介绍了记录治疗开发实验的关键要素。具体而言,我们描述了在分子、细胞、动物和临床模型中进行的实验。我们还提供了一组在I期临床试验中测试的治疗方法的要素示例。
我们引入了治疗实验信息指南(GIATE),这是一份最低限度信息清单,创建了一个一致的框架,用于透明地报告治疗实验的目的、方法和结果。文中介绍了对该指南的范围、设计和结构的讨论,以及预期受众的描述。我们还展示了补充资源,如分类方案,以及创建GIATE信息的两种替代方式:电子实验室笔记本和基于简单电子表格的格式。最后,我们使用GIATE记录了难治性淋巴瘤患者CHT - 25的I期临床试验细节。讨论了在此实验中使用GIATE的益处。
虽然正在制定数据标准以促进实验医学各个方面的数据共享和整合,如基因组学和临床数据,但以前没有工作专注于治疗开发。我们提出了一份治疗实验清单,并展示了其在131碘标记的CHT - 25嵌合抗体癌症治疗中的应用。作为未来的工作,我们将扩展GIATE工具集,继续鼓励癌症研究人员使用它,并且我们将设计一个本体来注释GIATE要素,促进明确的解释和数据整合。